Abstract: Salvia miltiorrhiza Bunge, also known as Danshen in Chinese, has been widely used to treat cardiovascular diseases (CVD) in China and other Asia countries. Here, we summarize literatures of the historical traditional Chinese medicine (TCM) interpretation of the action of Salvia miltiorrhiza, its use in current clinical trials, its main phytochemical constituents and its pharmacological findings by consulting Pubmed, China Knowledge Resource Integrated, China Science and Technology Journal, and the Web of Science Databases. Since 2000, 39 clinical trials have been identified that used S. miltiorrhiza in TCM prescriptions alone or with other herbs for the treatment of patients with CVD. More than 200 individual compounds have been isolated and characterized from S. miltiorrhiza, which exhibited various pharmacological activities targeting different pathways for the treatment of CVD in various animal and cell models. The isolated compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-CVD drugs. Meanwhile, there are also some rising concerns of the potential side effects and drug-drug interactions of this plant. The insights gained from this study will help us to better understanding of the actions of this herb for management of cardiovascular disorders. As an herb of red root, S. miltiorrhiza will act as a potential red light to prevent the development of CVD.
INTRODUCTION
Salvia miltiorrhiza Bunge, also known as red sage or Danshen (Chinese Pinyin name), is a perennial plant (Fig. 1A) in the genus Salvia of the mint family, Lamiaceae [1] . Its roots are highly valued as a ''super grade herb (herbs lacking observable toxicity)'' in the Shennong's Herbal Classic of Materia Medica (Shennong Bencao Jing) written during the reign of the Qin and Han dynasties (221 BC to 220 AD), and has been clinically used for more than 2000 years. Following this first record, S. miltiorrhiza was well described in classical traditional Chinese medicine (TCM) works such as in the Compendium of Materia Medica (Bencao Gangmu, Ming dynasty, 1596 AD). In the textbooks of academic TCM, S. miltiorrhiza is characterized as a common drug for promoting blood circulation and removing blood stasis. The herb has been officially recorded in the Chinese pharmacopoeia since 1953. According to the Chinese pharmacopoeia [2] , S. miltiorrhiza is the only official source of Salvia Radix & Rhizoma (Danshen) [3] . Phytochemical studies have shown that S. miltiorrhiza contained a large number of lipophilic diterpenoids (such as various tanshinone analogues), hydrophilic phenolic compounds (such as salvianolic acids), flavonoids, and triterpenoids) [4] [5] [6] [7] . S. miltiorrhiza has traditionally been used in the treatment of CVD [8] , such as atherosclerosis [9] , thrombosis [10] , and angina pectoris [11, 12] . And data about clinical information of hospitalized patients and outpatients with coronary artery Effective: Frequency of clinical symptoms attacks decreased by 50%; ECG ST segment elevated by more than 0.05 mV; Amplitude of lead T wave inversion decreased by more than 25%.
Ineffective: No change in ECG.
Markedly improved (23) .
Moderately improved (9) .
Ineffective (4).
Overall efficacy: 88.9%.
Control treatment: 75.0% using 40ml Shenmai injection + 250ml 5% glucose solution.
[24]
S. miltiorrhiza
Randomized controlled trial Cardiovascular disease 50 
weeks

Clinical efficacy:
Significant effect: Clinical symptoms completely improved alleviated by > 90%.
Effective: 50% < Clinical symptoms improvement ＜ 90%.
Ineffective: Clinical symptoms have no improvement or alleviated by ＜ 50%.
ECG efficacy:
Significant effect: ECG completely returned to normal.
Effective: ST-T wave almost returned to normal.
Ineffective: No improvement in ECG.
Clinical efficacy:
Markedly improved (33) .
Moderately improved (15) .
Ineffective (2).
Overall efficacy: 96%.
Control treatment: 86%, using Isosorbide Dinitrate tablet.
ECG efficacy:
Markedly improved (30) .
Moderately improved (17) .
Ineffective (3).
Overall efficacy: 94%.
Control treatment: 82%, using Isosorbide Dinitrate tablet. [25] Danshen and Gegen capsules Randomized placebo controlled trial (double blinded)
Postmenopausal women with borderline hypercholesterolemia 85 
months
Sitting blood pressure, resting ECG, and physical activity scale for the elderly questionnaire; Serum glucose, creatinine, low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride (TG).
Primary efficacy:
Carotid intima-media thickness decreased.
Secondary efficacy:
LDL and total cholesterol (TC) decreased.
Quality of life:
Improvement in general health and blood pressure. Markedly improved (13) .
Moderately improved (32) .
Ineffective (4).
Overall efficacy: 93.75%.
Control treatment: 75.0%, using Isosorbide Dinitrate tablets [27] Compound Danshen dripping pills Randomized controlled trial Coronary heart disease 33 
weeks
Symptoms of angina pectoris:
Significant effect: Angina pectoris disappeared completely or angina pectoris attacks decreased by ＞ 90%.
Effective: Angina pectoris attacks decreased by between 50% and 90%.
Ineffective: Angina pectoris attacks decreased by ＜ 50%.
ECG efficacy: Changes of ST-T wave, including load ECG.
Effective: ST-T wave returned to normal or changed from positive to negative.
Ineffective: No change in ST-T wave, load ECG test remained positive.
Symptoms of angina pectoris:
Markedly improved (24) .
Moderately improved (8) .
Ineffective (1).
Overall efficacy: 97.0%.
Control treatment: 84.8%, using Isosorbide Dinitrate tablets. [28] ( Cure: Clinical symptoms disappeared; Autonomic dysfunction disappeared; ECG and heart rate returned to normal.
Significant effect: Significant improvement in clinical symptoms; Heart rate decreased; ECG significantly improved; Autonomic nerve function returned to near normal.
Ineffective: No improvement or even worse in clinical symptoms.
Markedly improved (20) .
Moderately improved (16) .
Ineffective (3).
Overall efficacy: 92.31%.
Control treatment: 71.79% using Isosorbide Dinitrate tablets. [29] Compound Danshen dripping pills Randomized controlled trial Cardiovascular diseases 39 
weeks
Angina pectoris efficacy:
Ineffective: No obvious improvement in angina pectoris symptoms; Angina attacks decreased by ＜ 50% or even aggravated.
ECG efficacy:
Significant effect: ST segment returned to normal.
Effective: ST segment almost returned to normal.
Ineffective: No obvious changes in ST segment.
Angina pectoris efficacy:
Moderately improved (13) .
Ineffective (3).
Overall efficacy: 92.30%.
Control treatment: 46.15% using Isosorbide Dinitrate pills and Nifedipine.
ECG efficacy:
Markedly improved (21) .
Moderately improved (16 
Clinical efficacy:
Significant effect: (1) Exertional angina: Angina pectoris severity alleviated 2 grade; Grade 1-2 angina pectoris disappeared; Non-exertional angina pectoris: Clinical symptoms disappeared or almost disappeared; Angina attacks decreased by more than 90%; Resting ECG returned to normal; Submaximal exercise test changed from positive to negative or exercise tolerance increased by 2 levels.
Effective: (1) Exertional angina: Angina pectoris severity decreased by 1 level; Grade 1 angina pectoris disappeared;
(2) Non-exertional angina pectoris: Angina attacks decreased by > 50%; Resting ECG back to normal, or submaximal exercise test ECG ST segment elevated by more than 0.5 mV, but did not return to normal, or amplitude of lead T wave inversion decreased more than 50%, or shape of T wave changed from flat to upright, or exercise tolerance increased by 1 level.
Ineffective: No improvement in clinical symptoms, physical signs and ECG; Frequency of angina attacks decreased by 50%. blood viscosity and platelet aggregation rate significantly decreased.
Markedly improved (55) .
Moderately improved (34) .
Ineffective (5).
ECG efficacy:
Markedly improved (17).
Moderately improved (22) .
Ineffective (55).
Overall efficacy: 75%. [32] ( 
Angina pectoris efficacy:
Significant effect: Clinical symptoms such as chest stuffy, short of breath disappeared; Angina or frequency of angina attacks decreased in response to the same level of exertion; ECG ischemia returned to mormal.
Effective: Frequency of angina attacks decreased or chest congestion symptoms alleviated; ECG ischemia ST segment decreased; Shape of T wave changed from flat to upright.
Ineffective: No change in angina attacks and ECG.
Moderately improved (20) .
Ineffective (8).
Overall efficacy: 86.7%.
Control treatment 74%.
ECG efficacy:
Markedly improved (18) .
Ineffective (13).
Overall efficacy: 76.7%.
Control treatment using Isosorbide Dinitrate tablets. Serum TC and TG levels decreased.
ECG efficacy:
Markedly improved (25) .
Moderately improved (39).
Ineffective (10).
Overall efficacy: 86.5%.
Control treatment: 56.8% using Isosorbide Dinitrate tablets. [35] Compound Danshen dripping pills Randomized controlled trial Diabetes combined silent myocardial ischemia 45 Levels of adiponectin and homocysteine (Hcy).
Clinical efficacy:
Significant effect: ECG ST segment abnormalities improved or disappeared during the break.
Effective: ECG ST segment decreased or elevated by ＞ 0.05 mV during resting or sports; Amplitude of T wave inverted decreased by more than 50 %, and shape of T wave appeared upright or inverted.
Ineffective: No improvement in ECG, even more serious.
Markedly improved (30).
Moderately improved (14) .
Ineffective (1). Markedly improved (19) .
Moderately improved (27) .
Ineffective (4).
Overall efficacy: 92.0%.
Control treatment: 76.0% using aspirin. [37] ( Recovery (18) Markedly improved (12) .
Moderately improved (7).
Ineffective (3).
Overall efficacy: 92.5%.
Control treatment: 75.0% using Simvastatin.
[38]
Compound Danshen dripping pills + low molecular weight Heparin
Randomized controlled trial Coronary heart disease angina pectoris 80 1 month Significant effect: Angina pectoris almost disappeared or angina attacks decreased by more than 80%; ECG returned to normal or near normal.
Effective: Angina attacks decreased by between 50% and 80% or duration shorten; ECG ST segment elevated by more than 0.05 mV, but did not return to normal; Amplitude of T wave inversion decreased, or shape of T wave changed from flat to upright, or elevated ST segment decreased by more than 50%.
Ineffective: No improvement in angina pectoris; Elevated ST segment decreased by less than 50%, or even worse.
Frequency and duration of angina pectoris attacks decreased.
Markedly improved (42).
Moderately improved (29 Basically control (28) .
Moderately improved (19) .
Ineffective (8).
Overall efficacy: 89.33%.
Control treatment: 70.83% using Simvastatin. [43] ( 
Angina pectoris efficacy:
Markedly improved (26) .
Moderately improved (62).
Overall efficacy: 89.8%.
Control treatment 63.2%.
ECG efficacy:
Markedly improved (32).
Moderately improved (49).
Ineffective (17) .
Overall efficacy: 82.7%.
Control treatment: 54. 7% using Isosorbide Dinitrate tablet. 
Stable angina pectoris:
Markedly improved (51).
Moderately improved (11).
Ineffective (1).
Overall efficacy: 81%.
Control treatment 63.2%.
Unstable angina pectoris:
Moderately improved (4).
Ineffective (3).
Overall efficacy: 79%.
Control treatment: 54. 7% using basic treatment. [47] ( 
Angina pectoris efficacy:
Significant effect: Same level of exertion cannot induce angina, or frequency of angina attacks decreased by more than 80%.
Effective: Angina attacks or nitroglycerin consumption decreased by between 50% and 80%.
Ineffective: Angina attacks or nitroglycerin consumption decreased by ＜ 50%.
Aggravate: Frequency, duration and degree of angina attacks and nitroglycerin consumption increased.
ECG efficacy:
Significant effect: Resting ECG returned to normal or near normal.
Effective: ECG ST segment elevated by more than 0.05 mV; Amplitude of lead T wave inversion decreased by more than 25 %, or shape of T wave changed from flat to upright.
Ineffective: No improvement in resting ECG.
Angina pectoris efficacy:
Markedly improved (15).
Moderately improved (10).
Ineffective (4).
Aggravate: (1).
Overall efficacy: 83.3%.
Control treatment 50%.
ECG efficacy:
Markedly improved (10).
Ineffective (3).
Aggravate: (0).
Overall efficacy: 90%, Control treatment: 66.7% using Astragalus.
[48]
No control
Congestive heart failure 15
days
Ineffective: Symptoms of heart failure and physical signs markedly improved; Cardiac function improved by more than 2 levels.
Effective: Symptoms of heart failure and physical signs improved; Cardiac function improved by more than 1 level.
Significant effect: No improvement in symptoms of heart failure.
Markedly improved (8).
Moderately improved (6).
Ineffective (1).
Overall efficacy: 93%.
No control treatment. Platelet aggregation ratio decreased.
Control treatment using Alprostadil lipid emulsion injection.
[50]
Gehong decoction
No control Cardiovascular neurosis
23
Significant effect: Clinical symptoms completely disappeared.
Effective: Clinical symptoms obviously improved.
Ineffective: No change in clinical symptoms.
Markedly improved (21).
Moderately improved (2).
Ineffective (0).
Overall efficacy: 100%.
No Control treatment.
[51]
Tongxinluo capsule
Randomized controlled trial
Angina pectoris with coronary heart disease 48
weeks
Clinical efficacy:
Significant effect: Same level of exertion cannot induce angina pectoris, or angina pectoris attacks decreased by more than 80%.
Effective: Angina attacks decreased by between 50% and 80%.
Ineffective: Angina attacks decreased by ＜ 50%.
ECG efficacy:
Significant effect: Resting ECG returned to normal or/and submaximal exercise test changed from positive to negative, or exercise tolerance increased by more than 2 levels.
Effective: Resting ECG returned to normal or/and submaximal exercise test ECG ischemic ST segment elevated by more than 0.05mm, but did not return to normal; Amplitude of T wave inversion decreased by more than 50%, or T wave changed from flat to upright; Exercise tolerance improved by 1 level.
Ineffective: No change in ECG.
Clinical efficacy:
Moderately improved (12).
Ineffective (4).
Overall efficacy: 91.78%.
Control treatment 57.14%.
ECG efficacy:
Markedly improved (12) .
Ineffective (17).
Overall efficacy: 64.37%. 
Angina pectoris efficacy:
Significant effect: Frequency and duration of angina pectoris attacks decreased by more than 80 %.
Effective: Frequency and duration of angina pectoris attacks decreased by more than 50 %.
Ineffective: Frequency and duration of angina pectoris attacks decreased by less than 50 %.
ECG efficacy:
Significant effect: ECG returned to normal.
Effective: ST segment elevated by more than 0.05 mV, but did not return to normal; Amplitude of lead T wave inversion decreased by more than 25 %, or shape of T wave changed from flat to upright; Atrio-and intra-ventricular block improved.
Ineffective: No change in ECG.
Blood lipid efficacy:
Significant effect: TC decrease ≥ 20%; TG decrease ≥ 40%; HDL increase ≥ 0.26 mM; (TC-HDL)/HDL decrease ≥ 20 %. 
Angina pectoris efficacy:
Markedly improved (27) .
Ineffective (4).
Overall efficacy: 92%.
ECG efficacy:
Moderately improved (23) .
Ineffective (7).
Overall efficacy: 86%.
Control treatment 70%.
Blood lipid efficacy:
Markedly improved (18).
Moderately improved (22).
Ineffective (20) .
Overall efficacy: 80%.
Control treatment: 62% using aspirin, β-antagonist, calcium antagonists, nitrates. 
Markedly improved (24).
Moderately improved (5).
Ineffective (1).
Overall efficacy: 96.7%.
Control treatment: 76.7% using Perindopril. Effective: ST segment elevated by more than 0.05 mV, but did not return to normal; Amplitude of lead T wave inversion decreased by more than 25%, or shape of T wave changed from flat to upright.
Markedly improved (22).
Moderately improved (112) .
Ineffective (1).
Overall efficacy: 99.2%. Significant effect: Angina attacks decrease > 80%; Nitroglycerin consumption decrease > 80%, or same level of exertion cannot induce angina pectoris ; Resting ECG returned to normal.
Effective: 50%＜angina attacks and nitroglycerin consumption decrease ＜50%; Resting ECG ischemic ST elevation ≥ 0.1 mV; Amplitude of T wave inversion decreased by more than 25% or shape of T wave changed from flat to upright. Serum levels of Hcy, CysC and tumor necrosis factor-α (TNF-α) decreased; LVEF and E/A increased; Incidence of LVH, CHF decreased; CVC increased. [57] ( Effective: Frequency of angina attacks decreased by between 50% and 80%; Chest pain obviously alleviated during angina pectoris attack.
Ineffective: No obvious improvement in frequency of angina attacks and chest pain, or chest pain developed into acute myocardial infarction or sudden cardiac death.
ECG efficacy:
Significant effect: Resting ECG almost returned to normal.
Effective: Amplitude of ST segment increased by 0.1 mV; Amplitude of T wave inversion decreased by more than 50%, or shape of T wave changed from flat to upright.
Ineffective: No obvious improvement in ECG, or even appeared myocardial infarction during the attack.
Clinical efficacy:
Markedly improved (22) .
Ineffective (5).
Overall efficacy: 89.1%.
Control treatment 69.6%.
ECG efficacy:
Moderately improved (19 
Clinical efficacy
Ineffective (3).
Control treatment: 72% using conventional treatment. Frequency and duration of angina pectoris attacks, and heart rate improved.
Markedly improved (26).
Ineffective (3).
Overall efficacy: 93.43%.
Control treatment: 77.14% using composite salvia miltiorrhiza injection. The biological actions of these compounds isolated from S. miltiorrhiza have been clarified over the last few years, and several mechanisms have been proposed for the cardiovascular protection effects [67] of this plant, including anti-inflammation [1] , antioxidation [65, 68] anti-thrombosis [69] , anti-proliferation of vascular smooth muscle cells, inhibition of the expression of adhesion molecules in vascular endothelium and leukocytes [64, [69] [70] [71] , improvement of acute myocardial ischemia [72] , and so on [73] .
EFFECTS OF S. MILTIORRHIZA AND ITS ISOLATED COMPOUNDS ON THE DEVELOPMENT OF CVD IN ANIMAL EXPERIMENTS
The preclinical pharmacological effects of S. miltiorrhiza and its isolated compounds for the treatment of CVD have been extensively studied over the past few decades. The results have shown that S. miltiorrhiza offered therapeutic benefits on hypertension, atherosclerosis, myocardial ischemia and reperfusion injury in the animal experiments. The recent progress of S. miltiorrhiza in CVD animal disease models are summarized in Table 2 . In the following paragraphs, we review the recent advances of S. miltiorrhiza regarding cardiac protective effects in vivo and in vitro studies.
Effects of Salvia miltiorrhiza in the Development of Hypertension
Hypertension is a chronical medical condition in which the blood pressure in the arteries is persistently higher than it should be. Increased peripheral resistance, high cardiac output, an elevated heart rate, a reduction in the number or density of capillaries, increased active arteriolar vasoconstriction and decreased peripheral venous compliance account for the high pressure. Long term high blood pressure can cause coronary artery disease, stroke, heart failure and peripheral vascular disease [93] .
It is well established that Ca 2+ dependent and independent K + effluxes limit membrane depolarization and contraction and further buffer vascular resistance in arterial reactivity [94, 95] . Tanshinone IIA treatment (10 mg/kg for 4 weeks [83] or 21 days [84] , i.p.) attenuated chronic intermittent hypoxia or sustained hypoxia or monocrotaline (subcutaneous injection of 50 mg/kg [84] ) induced pulmonary artery wall remodeling (thickened small pulmonary artery vessel walls and deflated vessel lumina) and increased right ventricular systolic pressure (RVSP) in rats. The underlying mechanisms for these improvements may be attributed to modulate the expressions of K V 2.1 and K V 1.5 [83] , and to inhibit basal intracellular Ca 2+ concentration and store-operated Ca 2+ entry (SOCE) via attenuating the expressions of canonical transient receptor potential (TRPC) 1 and TRPC 6 [84] . However, Tanshinone IIA did not affect rats RVSP and the mean carotid arterial pressure under normoxia exposure.
Connexins (Cxs) and endothelial nitric oxide synthase (eNOS) harmonize the adaptation of smooth muscle cells and endothelial cells. Using spontaneously hypertensive rats, Tang et al. found that administration of Danshensu (10 mg/kg/d for 6 weeks) decreased blood pressure and inhibited arrhythmias via increasing serum nitric oxide (NO) content and nitric oxide synthase activity [74] . Using isoproterenol (2.5 mg/kg/d for 7 days, s.c.) induced myocardial hypertrophy rats, Danshensu treatment (3 and 10 mg/kg/d from day 4 to 7 of isoproterenol treatment, i.p.) reduced heart/body weight index and arrhythmia scores as well as improved left ventricle systolic pressure and left ventricle end diastolic pressure and electrocardiogram parameters by regulating antioxidant enzymes and promoting left ventricular Cx-43 expression [85] .
Matrix metalloproteinases and tissue inhibitors of metalloproteinases (MMPs/TIMPs) impact vascular relaxation/contraction via regulating ion channels in the endothelium and vascular smooth muscle during vascular remodeling [96, 97] . Fang et al. demonstrated that supplyment with tanshinone IIA (70 mg/kg/d for 6 weeks) prevented cardiac fibrosis and left ventricular hypertrophy as well as improved cardiac relaxation in 2-kidney-2-clip induced renovascular hypertension rats [76] . Tanshinone IIA conferred its beneficial effects by decreasing collagen volume content via decreasing mRNA levels of MMP-9, TIMP-1 and TIMP-2 and increasing the mRNA ratio of MMP-2 to TIMP-2 [76] .
Angiotensin-converting enzyme (ACE) controls the fluidelectrolyte balance and blood pressure through converting the hormone angiotensin (Ang) I to the active vasoconstrictor Ang II and subsequently causing blood vessels to constrict [98, 99] . Addition of lithospermic acid B (10-1000 μg/ml) dose-dependently inhibited ACE plasma activities. Lithospermic acid B (100-400 μg/ml) treatment also attenuated Ang I induced contraction in the endothelium intact aortic rings [100] .
Hypertension is associated with elevated myocardial tumor necrosis factor-α (TNF-α) production [101] . S. miltiorrhiza (1 g/kg for 12 weeks, i.p.) treatment decreased left ventricular mass index, cardiomyocytes sizes, collagen volume fraction, perivascular circumferential area through regulating TNF-α expression in spontaneously hypertensive rats [75] . Interestingly, the investigator claimed that the cardio protective effect of this herb was independent of blood pressure.
Further, magnesium tanshinoate B (MTB, 0.7-175 mg/kg via the jugular vein) was evidenced to exhibit hypotensive effect on phenylephrine induced elevated blood pressure in male SD rats [86] . Tian et al found that S. miltiorrhiza (0.125 g/mouse) and salvianolic acid B (0.5 mg/mouse) decreased the average blood flow velocity in liver in endothelin (ET)-1 induced portal hypertension mice evaluated by laser-Doppler flow instrument [87] . But the mechanisms remain unclear.
Taken together, Salvia miltiorrhiza and its ingredients, including lithospermic acid B, tanshinone IIA and Danshensu, offer therapeutic promise on hypertension through regulating expressions of TRPC/Ca 2+ , Cx/eNOS/ET-1, MMP/TIMPs, ACE and TNF-α. However, the underlying mechanisms for their pharmacological actions of salvianolic acid B and tanshinoate B still remain unknown. Besides spontaneously hypertensive rats, a lot of measures are employed to evaluate anti-hypertensive effects of the herbs, such as hypoxia, monocrotaline, 2-kidney-2-clip, Ang I, phenylephrine and ET-1. These efforts may afford experimental evidences for clinical use of this herb.
Effects of Salvia miltiorrhiza in the Development of Artherosclerosis
Atherosclerosis is a condition where the arteries become narrowed and lost of elasticity of the artey walls due to an excessive build up of sticky plaques within the arterial intima [102, 103] . S. miltiorrhiza exihibits beneficial effects for the treatment of artherosclerosis through the following manners.
First, S. miltiorrhiza has the ability of inhibiting oxidative stress. Oxidative stress leads to aggravation of endothelial cells and disruption of vascular wall microenvironment as well as overexpression of adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which induced cardiac dysfunction [104] . By preventing low density lipoprotein (LDL) from oxidation, S. miltiorrhiza (5% water-soluble extract of S. miltiorrhiza for 12 weeks) reduced the atherosclerotic area in the abdominal aorta by 56% and cholesterol deposition in the thoracic aorta by 50% in cholesterol-fed rabbits [80] . In vitro, both S. miltiorrhiza and salvianolic acid B exhibited free radical scavenging activity in DPPH assay, and were also effective in preventing Cu 2+ induced LDL oxidation [80] . Further, Inhibition of the translocation of nuclear transcription factor-kappa B and suppressed expression of inflammatory cytokines (TNF-α, interleukin-1 β), and decreased the myeloperoxidase activity.
[77]
Porcine closed-chest model Salvianolate;
10 mg/kg/day.
7 days Improvement in myocardial perfusion; Increase in capillary density and decrease in infarct sizes; Elevatation of superoxide dismutase (SOD) activity, thioredoxin activity and glutathione concentration; Decrease in malondialdehyde concentration.
[78]
Myocardial ischemia rats Decrease in blood pressure.
[86]
Endothelin-1 induced portal hypertension mice S. miltiorrhiza; 0.125 g/mouse.
Salvianolic acid B; 0.5 mg/mouse.
days
Decrease in the average blood flow velocity in liver.
[87]
Isolated rat hearts of ischemia reperfusion (I/R) Danshensu; 1 and 10 µM.
The extract of S. miltiorrhiza; 29.76 or 59.52 mg/kg.
Increase in CF, heart rate, left ventricular developed pressure, and the recovery of ± dp/dtmax; Decrease in infarct sizes; Inhibition of oxidative stress through regualting Akt/extracellular signal-regulated kinase 1/2/nuclear factor erythroid-2-related factor 2 signaling pathway. [88, 89] Apolipoprotein Edeficient mice
Cryptotanshinone; 15 and 45 mg/kg/day.
weeks
Significant reduction in atherosclerotic plaque formation and enhanced plaque stability; Decrease in lectin-like oxidized LDL receptor-1 (LOX-1) and matrix metalloproteinase (MMP)-9.
[90]
( -ATPase activities; Alleviatation of oxidative stress; Inhibition of myocardial apoptosis [92] tanshinone IIA treatment (15 and 37.5 mg/kg for 2 months by gavage) reduced malondialdehyde (MDA) level and increased superoxide dismutase (SOD) activity in high fatty diet (HFD) induced atherosclerosis rabbits [1] . Zhiping Liu et al. showed that treatment with cryptotanshinone (15 and 45 mg/kg/day) resulted in a significant reduction in atherosclerotic plaque formation and enhanced plaque stability in HFD insulted apolipoprotein E deficient mice by reducing the expressions of lectin-like oxidized LDL receptor-1 (LOX-1) and MMP-9 through inhibiting NADPH oxidase 4 (NOX4)-mediated ROS generation and consequent nuclear transcription factor-kappa B (NF-κB) activation [90] . Treatment with salvianolic acid B (8 m/kg/d) and tanshinone IIA (24 mg/kg/d) for 8 weeks were demonstrated to inhibit atherogenesis of HFD-fed rabbits by increasing NO release [9] .
Second, S. miltiorrhiza is effective in inhibiting inflammation in the development of CVD. Inflammatory mediators increase local susceptibility to plaque formation which contributes to the development of atherosclerosis [105] . Using atherosclerosis rats challegened by HFD, salvianolate treatment dose-dependently (60, 120 and 240 mg/kg for 12 weeks, i.p.) alleviated the atherosclerotic process via decreasing the levels of proinflammatory cytokines (plasma interleukin-6 (IL-6) and C reactive protein (CRP)) and increasing the number of regulatory T cells (Tregs) (cluster of differentiation (CD)4+CD25+Foxp3+) [82] . Tregs is demonstrated to prevent the development of atherosclerosis by reducing IL-6 expression [106] and CRP production [107] . Interestingly, although salvianolate treatment did cause a decrease in the levels of total cholesterol and LDL, it had no effect on that of triglyceride and HDL.
Platelet CD40 stimulates activations of leukocyte and endothelial cells and further promotes atherosclerosis [108] . Meanwhile, increased MMP-2 activity potentiates inflammation insults and plaque instability in the injured vascular wall [109] . Tanshinone IIA was demonstrated to downregulate CD40 expression and decrease MMP-2 activity in atherosclerosis rabbits [1] .
In a rat carotid artery balloon injury model, magnesium lithospermate B treatment (10 mg/kg/day for 28 days, i.p) prevented neointimal formation [68] . Wan et al studied the effect of the lipophilic fraction (tanshinone IIA and cryptotanshinone) of S. miltiorrhiza roots on isolated porcine coronary arteries induced by U46619 (a thromboxane A analogue). The results demonstrated that the lipophilic fraction at a concentration of 0.1 mg/mL induced complete relaxation in porcine coronary artery [110] . However, the mechanisms responsible for these effects still warrant further investigation.
In short, S. miltiorrhiza and its ingredients may serve as antioxidant and anti-inflammation agents to prevent the development of atherosclerosis. S. miltiorrhiza, salvianolic acid B, tanshinone IIA, salvianolate and cryptotanshinone are well studied in this respect.
Meanwhile, HFD induced atherosclerotic rabbit and rat models are employed to evaluate the effect of this herb on atherosclerosis.
Effects of S. miltiorrhiza in the Improvement of Myocardial Ischemia (MI)
Myocardial ischemia (MI, also known as angina) is a heart condition caused by a lack of blood supplement to the heart, which is the result of a partial or complete blockage of coronary arteries and may consequently accelerate the deterioration of cardiac function [17] . Reperfusion therapy is the most effective therapeutic strategy for improving the prognosis of patients with acute myocardial infarction but accompanied with the potential risk of worsening tissue damage after ischemia [17, 111, 112] . MI exerts multiple insults in myocardium, frequently accompanied by reactive oxygen species (ROS) generation, intracellular calcium overload, myocardial apoptosis, endothelial dysfunction, enhanced adhesion of leukocytes and mast cell degranulation [71, 113, 114] .
Using real-time myocardial contrast echocardiography and coloured microspheres techniques, Han et al. demonstrated that adminstration with salvianolate (10 mg/kg/day for 7 days, i.v.) improved myocardial microvascular reflow and increased capillary density as well as decreased infarct sizes in a porcine closed-chest model [78] . The beneficial effect of salvianolate was probobaly related to its ability of decreasing oxidative stress and apoptosis, which was supported by elevated SOD activity, thioredoxin activity and glutathione concentration, and reduced MDA concentration, as well as decreased terminal deoxynucleotide transferase-mediated dUTP nick end labelling-positive cells and increased ratio of B-cell lymphoma 2 to Bax expression [78] .
Monocyte chemotactic protein (MCP)-1 is upregulated in the development of MI both in clincal trial [115] and animal model [116] , which facilliates infiltration, activation and cytokine secretion of inflammatory cells. MCP-1 null mice exhibited decreased macrophage recruitment in the infarcted heart, delayed phagocytosis of dead cardiomyocytes, diminished fibroblast infiltration and attenuated left ventricular remodeling [117] . Meanwhile, Ang II and TNF-α stimulate MCP-1 production [118] and amplify the proinflammatory response through NF-κB and mitogen activated protein kinase (MAPK) p38 signaling pathway [119, 120] . Tanshinone IIA (60 mg/kg/day for 7 days) treatment decreased infarct sizes and collagen deposition and improved heart recovery in permanent left anterior descending coronary artery (LAD) ligation induced MI rats [81] . The cardioprotective effect of tanshinone IIA could be attributed to its abilty of inhibiting inflammatory responses by reducing expressions of MCP-1, transforming growth factor (TGF)-β1, TNF-α and NF-κB [81] . In addition, tanshinone IIA (2-8 μM) treatment also reduced MCP-1 and TGF-β1 secretion in TNF-α stimulated cardiac fibroblasts [81] .
In addition, Danshensu (1 and 10 µM) [88] and the extract of S. miltiorrhiza (29.76 or 59.52 mg/kg for 5 days by gavage) [89] treatment contributed to the recovery of cardiac function after MI, and the tolerance of heart against MI injury by improving coronary flow, heart rate and left ventricular developed pressure, and the recovery of ± dp/dt max as well as reducing infarct sizes via inhibiting oxidative stress through regualting Akt/extracellular signalregulated kinase (ERK) 1/2/nuclear factor erythroid-2-related factor 2 (Nrf2) signaling pathways in isolated rat hearts MI model.
Jin et al. observed the effect of cryptotanshinone treatment in LAD induced MI rats. They oberved the alterations of hemodynamic parameters (left ventricular end diastolic pressure and ± dp/dt max ) and the infarct area as well as area at risk. The results demonstrated that cryptotanshinone (250 μg/kg) reversed the MI induced alterations by modualting inflammatory pathway evidenced via inhibiting NF-κB translocation and reducing expressions of proinflammatory cytokines (TNF-α, IL-1β and IL-6) as well as suppressing neutrophil infiltration and myeloperoxidase activity through regualting p38 mitogen-activated protein kinase (MAPK)/ c-Jun N-terminal kinase (JNK)/ERK in ischemic myocardial tissues [77] .
Activation of the cardiac angiogenesis program is a promising therapeutic strategy to match the increasing demands of oxygen and nutrients in the stressed heart [121] . The hypoxia-inducible factor 1α (HIF1α) and vascular endothelial growth factor A (VEGFA) contribute to cardiac angiogenesis [122] . Employing LAD induced MI mice, Danshen (3 and 6 g/kg/day for 4 weeks, i.p.) was proved to increase HIF1α and VEGFA expression which futher contributed to improving cardiac function and cardiac angiogenesis [91] .
Song et al oberved the effect of S. miltiorrhiza polysaccharides on LAD induced MI rats. They found that pretreatment with S. miltiorrhiza polysaccharides (400 and 800 mg/kg for 1 week) reduced the infarct sizes and improved Na + -K + -ATPase and Ca
2+ -Mg
2+
-ATPase activities by alleviating oxidative stress and inhibiting myocardial apoptosis [92] . It is known that myocardial Na -ATPase activities are associated with myocardial damage such as ischemic cardiac dysfunction and arrhythmias [123] .
Using LAD induced MI rats, Lu et al. [79] found that salvianolic acid B (20 mg/kg/d for 7 days) treatment was effective in resolving MI. They demonstrated that salvianolic acid B achieved its therapeutic effect by improving some of biomarkers, including 15(S)-HETE, 2',3'-cyclic adenosine monophosphate (cAMP), dihydrosphingosine, phytosphingosine, L-isoleucyl-L-proline, 2',3'-cyclic guanosine monophosphate, 1-phenylethylamine, thromboxane B2, hypoxanthine, L-homoserine, carnosine, allantoin, Lvaline, L-phenylalanine, dihydrobiopterin, 2-oxoisocaproic acid, Lisoleucine, L-tryptophan and glyceraldehydes. However, the authors did not conduct further experiments to verify these alterations.
In conclusion, Danshen, the extract of S. miltiorrhiza, salvianolate, tanshinone IIA, Danshensu, cryptotanshinone, S. miltiorrhiza polysaccharides and salvianolic acid B are demonstrated to exhibit protective effect on MI through scavenging oxidative stress, reducing inflammation and improving angiogenesis via regualting p38MAPK/JNK/ERK and Akt/ERK1/2/Nrf2 pathways. Among these, S. miltiorrhiza polysaccharides also showed its beneficial role against MI. Given lack of effective measures to determine its contributors, there is still a long way to go for exploiting contributions of polysaccharides for the treatment of CVD.
Effects of Salvia miltiorrhiza on Endothelial Cells, Smooth Muscle Cells and Myocardial Cells
The Protective Effects of Salvia miltiorrhiza on Endothelial Cells
The vascular endothelium, positioned at the interface between blood and tissue, plays a pivotal role in maintaining the integrity of the vessel wall. The death or injury of endothelial cells may contribute to the initial endothelial pathophysiological processes, including angiogenesis, atherosclerosis, and thrombosis.
NO plays the cardioprotective role through regualting blood pressure and vascular tone, and inhibiting platelet aggregation and leukocyte adhesion as well as preventing smooth muscle cell proliferation. An impairment of NO production may result in hypertension or atherosclerosis [124] . Further, ET-1 is a vasoconstricting peptide produced primarily in the endothelium which contributes to constrict blood vessels and raise blood pressure. Activating transcription factor (ATF)-3 mediated inflammatory and apoptotic responses as well as oxidantvie stress in the endothelium [125] . NO promotes ATF-3 expression and further results in a repression of MMP-2 promoter activity [126] . Tanshinone IIA (3 and 10 μM [127] ; 0-100 μM [128] ) treatment inhibited ET-1 release and stimulated NO production via inducing eNOS activation and ATF-3 expression in human umbilical vein endothelial cells (HUVECs). Further, tanshinone IIA (3-10 μM) exhibited resistance to H 2 O 2 induced apoptosis via decreasing CD40 expression [129] and inducing ATF-3 expression [130] in HUVECs.
Cryptotanshinone also exhibits mitigating effects against oxidative stress and inflammation insults. Using HUVECs exposed to H 2 O 2 , TNF-α and oxidized LDL insults [77, 90] , cryptotanshinone treatment was shown to inhibit the resultant NF-κB activity and LOX-1 expression. Further, cryptotanshinone inhibited LOX-1-mediated adhesion of THP-1 monocytes to HUVECs by reducing the expression of VCAM-1, ICAM-1 and E-selectin via inhibiting NOX4/ROS/NF-κB signaling pathway in HUVECs [90, 131] . It is accepted that increased expression and activation of ICAM-1 and VCAM-1 as well as E-selectin contribute to the attachment of circulating monocytes/leukocytes to the surface of endothelial cells, which initials atherosclerosis [132] .
Vascular endothelial growth factor (VEGF) regulates the endothelial hyperpermeability which resulted in inflammation and subsequent ischemic reperfusion injury or atherosclerosis. The extracts of S. miltiorrhiza and its active components (Danshensu and salvianolic acid B) inhibited TNF-α induced hyper-permeability by inhibiting VEGF expression [133] in HUVECs. In addition, salvianolic acid B and Danshensu (1-20 μg/ml) also protected HUVECS against hydrogen peroxide damage [65] .
Danshen aqueous extract and its pure compounds (Danshensu, protocatechuic acid, catechin and protocatechualdehyde at dose of 10 μg/ml) protected HUVEC against homocysteine-induced endothelial dysfunction by tube formation assay. The efficacy was demonstrated as the following descending order: Danshen aqueous extract, Danshensu, protocatechuic acid, catechin and protocatechualdehyde [134] .
The Protective Effects of Salvia miltiorrhiza on Smooth Muscle Cells
Vascular smooth muscle cells (VSMCs) are one of the major constituents of blood vessel walls and deeply involved in the development of CVD. Wang et al. demonstrated that tanshinones (a mixture of tanshinone I, tanshinone II, and cryptotanshinone at the dosages of 0.4, 2, 10 and 50 μg/ml) inhibited VSMCs proliferation by decreasing ERK1/2 signaling as well as decreasing the cyclin D expression through increasing the p21 waf1/cip1 expression, which are essential for cell cycle progression from G0/G1 phase to S Phase [70] . Tanshinone IIA (12.5 μM) treatment also inhibited hypoxia (4% O 2 , 60 h) induced pulmonary artery smooth muscle cells (PASMCs) proliferation and migration, and suppressed prolonged hypoxia induced TRPC expression in PASMCs from normoxic rats [84] .
TRPC proteins may act as molecualr components of storeoperated Ca 2+ channels which mediate Ca 2+ influx [135] . Elevation of intracellular Ca 2+ concentration ([Ca 2+ ] i ) contributes to cell growth and contraction [136] . Administration of sodium tanshinone IIA sulfonate (10 mg/kg) reduced SOCE and inhibited elevation of basal [Ca 2+ ] i through supressing TRPC1 and TRPC6 expression in distal PASMCs from chronical hypoxic rats [84] .
Acute hypoxia inhibits K V channel function and triggers contraction in PASMCs [137] . Tanshinone IIA (25 μg/ml) partly reversed acute hypoxia (pO 2 at about 15 mmHg for 30 min) induced downregulated I KV currents in PASMCs [83] .
Using primary mesenteric vascular smooth muscle cells isolated from spontaneously hypertensive rats, Danshensu treatment enhanced the K + and Ca 2+ activated K + channel current density when the test potential was set at +60 mV [74] . Ca 2+ -activated K + (K Ca ) channels along with K + (K V ) channels play an important role in regulating vascular tone and blood pressure [138] .
Both phosphatidylinositide 3 kinase (PI3K)/Akt and MAPK/ERK pathways are involved in regulating smooth muscle cells [139, 140] . Tanshinone IIA was able to inhibit human aortic smooth muscle cell migration by inhibiting phosphorylation of Akt and ERK and c-jun. Meanwhile, tanshinone IIA also has the ability of reducing MMP-9 activity and NF-κB activation [141] .
Following endothelial injury and excessive oxidative stress, VSMCs proliferate and migrate to the intima, leading to intima hyperplasia and development of CVD [10, 142, 143] . In an experiment performed by Hur et al. demonstrated that magnesium lithospermate B (10 μM) attenuated platelet-derived growth factor-BB induced VSMCs proliferation and migration via inhibiting phosphorylation of PI3K/Akt and MAPK/ERK pathways by scavenging reactive oxygen species [68] .
In addition, dimethyl lithospermate B was effective in eliminating the arrhythmogenic substrate which was responsible for the Brugada syndrome by slowing I Na inactivation via increased inward current during the early phase of the action potential in canine [144] . It maybe use as a pharmacological adjunct to implantable cardioverter/defibrillator usage.
The Protective Effects of Salvia miltiorrhiza on Myocardial Cells
The hypertrophy of myocardial cells impairs myocardial contractility and leads to LV hypertrophy [145] . Tanshinone VI (10 μM) attenuated ET-1, phenylephrine, or insulin like growth factor-1 (IGF-1) induced increases in protein synthesis in neonatal rat cardiac myocytes. Tanshinone VI (10 μM) treatment attenuated fetal bovine serum (5%) or IGF-1 (0.01 μM) induced hypertrophy via decreasing collagen synthesis in cardiac fibroblasts [146] . Thus, tanshinone VI may improve the development of cardiac remodeling under pathophysiological conditions.
In the development of MI, cAMP activates protein kinase A (PKA) which results in phosphorylation of L-type Ca 2+ channel and consequent Ca 2+ influx, leading to stronger muscle contraction. Salvianolic acid B treatment (0.001, 0.01 and 0.1 mg/mL for 2 h) decreased Ca 2+ and cAMP, and inhibited PKA in H9C2 cell (a myogenic cell line derived from embryonic rat heart ventricle) [79] .
In addition, S. miltiorrhiza is reported to be an effective inhibitor of Ang II action. However, the different fractions of the roots of S. miltiorrhiza exhibited different effects on Ang II treated neonatal rat cardiac cells (cardiomyocytes and non-cardiomyocytes). The ethyl acetate insoluble fraction from the methanol extract attenuated hypertrophy of cardiomyocytes. The methanol eluate fraction of the water extract treatment inhibited hyperplasia of non-cardiomyocyte [147] .
To summarized in vitro experiments, S. miltiorrhiza and its active ingredients (Danshensu, salvianolic acid B, protocatechuic acid, catechin, protocatechualdehyde, tanshinone, tanshinone IIA, lithospermate B, tanshinone VI and cryptotanshinone) exhibit protective effects in CVD disease models of endothelial cell and smooth muscle cells as well as myocardial cells through mutiple targets.
Furthermore, S. miltiorrhiza is also synergistically cooperated with other herbs (Radix Puerariae Lobatae [148] [149] [150] , Compound Danshen tablet [151] , Fufang Xueshuantong capsule [152] ), Danhong injection [153] , or western drug (Atorvastatin [154] ) to treatment of CVD animals. However, it is reported that tanshinones and S. miltiorrhiza root extracts contained potent human carboxylesterase (CE) inhibitors, while CEs hydrolyze clinically used drugs [155] . For drug interactions of this herb, interested readers are encouraged to consult Su et al's review [16] . Therefore, remedies containing tanshinones should be alerted for potential drug-drug interactions when patients are taking additional western drugs.
Currently, there is a rising concern about the safety of S. miltiorrhiza products. And a few investigators reported potential side effects, such as abdominal discomfort [5, 156] , decreased appetite, convulsions, dystonia syndromes [157] , and allergy [158] . However, these side effects are relieved when patients stop taking the medications [16] . Meanwhile, these observations are not well designed. Thus, the clinical physicians still need strong and scientific evidences to make sure whether Salvia miltiorrhiza is suitable for long term consuming.
In summary, S. miltiorrhiza and its ingredients (Danshensu, salvianolic acid B, protocatechuic acid, catechin and protocatechualdehyde, tanshinone, tanshinone IIA, tanshinone VI, lithospermate B, cryptotanshinone and polysaccharides) are extensively studied in animal and cell disease models of CVD. The results reveal that S. miltiorrhiza plays beneficial roles in improving CVD, such as atherosclerosis, hypertension and myocardial ischemia. These pharmacological activities are associated with scavengering oxidative stress and resolving inflammation as well as improving angiogenesis via regulating TRPC/Ca 2+ , Cx/eNOS/ET-1, MMP/ TIMPs, p38MAPK/JNK/ERK, Akt/ERK/Nrf2 and Nox4/ROS/NF-κB pathways. The researchers and clinical physicians should pay attention to the potential side effects and drug-drug interactions.
CONCLUSION AND OUTLOOK
S. miltiorrhiza is one of the most frequently used herbs in formulations prescribed for the clinical treatment of CVD in China. Since 2000, there are 39 clinical trials used S. miltiorrhiza to treat CVD. Although most studies reported promising efficacy in improving clinical symptoms, their significance is still need to be improved through well designed clinical trials in order to provide sufficient evidence to fully demonstrate the effects of S. miltiorrhiza products. The investigators are also needed to pay more attention to potential adverse effects and drug-drug interactions of this herb. Currently, there have been more than 200 compounds have been identified from S. miltiorrhiza Bunge. Most of these compounds exhibit multipotent pharmacological activities. Various in vitro and in vivo preclinical experiments showed S. miltiorrhiza and its ingredients could lower hypertension, improve atherosclerosis and myocardial ischemia reperfusion. The identified active compounds, including Danshensu, salvianolic acid B, protocatechuic acid, catechin, protocatechualdehyde, tanshinone, tanshinone IIA, tanshinone VI, lithospermate B, cryptotanshinone and polysaccharides, are considered to be responsible for its cardioprotective effects through different cell signaling pathways. Fig. (3) briefly illustrates the different pharmacological activities of S. miltiorrhiza and its ingredients. The results strongly support the notion that S. miltiorrhiza has beneficial therapeutic properties and has a potential of being an effective alternative remedy for the management of CVD.
Taditional clinical Chinese medicine illuminates the possible indications of S. miltiorrhiza for patients with CVD. However, the potential pharmacological effects are still required to be studied by more strong scientific evidences. Furthermore, the holistic and dialectical approach of TCM theory suggests the scientists to probe the possible synergistic actions among multiple constituents of this herb and other co-prescribed herbs. More new drugs are expected to source from this plant with better therapeutic effects and lower side effects by mining the ingredients. The existing ingredients in this plant are useful for developing potent compounds drugs, which may offer synergistic actions and exhibit better anti-CVD effects compared to the individual compound. These approaches are also useful for guiding our research to employ an integrative therapeutic approach to treat complex diseases such as CVD which could be superior to the conventional single target -single drug approach. This will shed the light on TCM researchers and patients with CVD around the world, and will also benefit for the development of TCM herbs such as S. miltiorrhiza in the near future. 
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